A Pilot Study of Atomoxetine for Freezing of Gait in Parkinson's Disease (ATMFOG)

NCT03651856 Phase 3 COMPLETED Results posted

Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.

Details

Lead sponsor	Medical University of South Carolina
Phase	Phase 3
Status	COMPLETED
Enrolment	10
Start date	2013-01
Completion	2014-02

Conditions

• Parkinson's Disease
• Freezing of Gait

Interventions

• ATM FOG in PD

Primary outcomes

• Number of Participants With Treatment Emergent Adverse Events — week 8
  Evaluate the safety of Atomoxetine 40mg bid in PD patients with FOG (Freezing of Gait)

Countries

United States